Resources

Type of publications
Regions
Diseases
4864 results found
2024 ∙ Nealon, J. Mefsin, Y. M. McMenamin, M. E. Ainslie, K. E. C. Cowling, B. J.
Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis
All age groups COVID-19 Efficacy/effectiveness Administration
Rating:
Critically low
2024 ∙ Mapindra, M. P. Mahindra, M. P. McNamara, P. Semple, M. G. Clark, H. Madsen, J.
Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy
Pregnant women Newborn RSV (Respiratory syncytial virus) Safety Efficacy/effectiveness
Rating:
Critically low
2024 ∙ Phijffer, Ewem de Bruin, O. Ahmadizar, F. Bont, L. J. Van der Maas, N. A. T. Sturkenboom, Mcjm Wildenbeest, J. G. Bloemenkamp, K. W. M.
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes
Pregnant women RSV (Respiratory syncytial virus) Efficacy/effectiveness Safety
Rating:
High
2024 ∙ Srichawla, B. S. Fang, T. Kipkorir, V. Garcia-Dominguez, M. A.
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review
Adults Older adults COVID-19 Measles Safety
Rating:
Critically low
2024 ∙ Vladulescu-Trandafir, A. I. Bojinca, V. C. Munteanu, C. Anghelescu, A. Popescu, C. Stoica, S. I. Aurelian, S. Balanescu, A. Baetu, C. Ciobanu, V. Onose, G.
Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review
All age groups COVID-19 Efficacy/effectiveness Safety
Rating:
Critically low
2024 ∙ Gupta, P. C. Padhi, B. K. Abu Serhan, H. Dziedzic, A. Khatib, M. N. Gaidhane, S. Zahiruddin, Q. S. Gaidhane, A. M. Kukreti, N. Rustagi, S. Satapathy, P.
Risk of Corneal Transplant Rejection Following COVID-19 Vaccination: A Systematic Review and Meta-analysis
All age groups COVID-19 Safety
Rating:
Critically low
2024 ∙ Shabani, M. Shobeiri, P. Nouri, S. Moradi, Z. Amenu, R. A. Mehrabi Nejad, M. M. Rezaei, N.
Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis
All age groups COVID-19 Safety
Rating:
Critically low
2024 ∙ Bianchi, F. P. Polignano, M. Carella, N. Rotolo, O. Curlo, M. Mastronardi, M.
Role of gastroenterologists and healthcare providers in promoting COVID-19 immunization among individuals with inflammatory bowel disease: A systematic review and meta-analysis on a global scale
All age groups COVID-19 Acceptance
Rating:
Not applicable
2024 ∙ Zhuo, Y. Lu, Z. Zhang, X. Yang, Y. Han, J. Du, J. Xu, Y. Liu, Y. Fu, C.
Rubella antibody levels in the healthy Chinese population: a meta-analysis
Western Pacific China All age groups Rubella Efficacy/effectiveness
Rating:
Critically low
2024 ∙ Seyedalinaghi, S. Pashaei, A. Tantuoyir, M. M. Karimi, A. Mojdeganlou, H. Nazarian, N. Vahedi, F. Afzalian, A. Shobeiri, P. Dashti, M. Ghasemzadeh, A. Mirzapour, P. Parikhani, S. N. Mehraeen, E.
Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review
All age groups COVID-19 Safety
Rating:
Critically low
Loading...